Daniel Bergström

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial

Brigitte Dréno, Rainer Kunstfeld, Axel Hauschild et al. · The Lancet Oncology · 2017 · 206 citations

Medicine, Oncology, Pharmacology +12

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Anna Johnsson, Helga Hagman, Jan‐Erik Frödin et al. · Annals of Oncology · 2013 · 75 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Lack of responsiveness to TGF-β1 in a thyroid carcinoma cell line with functional type I and type II TGF-β receptors and Smad proteins, suggests a novel mechanism for TGF-β insensitivity in carcinoma cells

Nils‐Erik Heldin, Daniel Bergström, Annika Hermansson et al. · Molecular and Cellular Endocrinology · 1999 · 30 citations

Medicine, Molecular Biology, Oncology +14

Collagen type I expression in experimental anaplastic thyroid carcinoma: Regulation and relevance for tumorigenicity

Thérèse Dahlman, Ellen Lammerts, Daniel Bergström et al. · International Journal of Cancer · 2001 · 30 citations

Medicine, Cell Biology, Oncology +11

A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer

Kenneth Villman, John Öhd, Elisabet Lidbrink et al. · European Journal of Cancer · 2007 · 21 citations

Medicine, Oncology, Pharmacology +16